Clinical Trial Update: A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating autologous renal cell therapy (REACT) in patients with diabetic chronic kidney disease has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• REACT (Renal Autologous Cell Therapy)

Snippet

Sponsor: Prokidney | Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-03-24